harmful (H) for the patient; statistically nonsignificant findings are designated as equivocal (E). 83 Level 1: The literature contains a sufficient number of RCTs to conduct meta-analysis, § and 84 meta-analytic findings from these aggregated studies are reported as evidence. 85
Level 2: The literature contains multiple RCTs, but the number of RCTs is not sufficient to 86 conduct a viable meta-analysis for the purpose of these updated Guidelines. Findings from these 87
RCTs are reported separately as evidence. 
Inferred findings are given a directional designation of beneficial (B), harmful (H), or equivocal (E). 92
For studies that report statistical findings, the threshold for significance is p < 0.01. 93
Level 1: The literature contains observational comparisons (e.g., cohort, case-control research 94 designs) with comparative statistics between clinical interventions for a specified clinical outcome. 95
Level 2: The literature contains non-comparative observational studies with associative statistics 96 (e.g., relative risk, correlation, sensitivity/specificity). 97
Level 3: The literature contains noncomparative observational studies with descriptive statistics 98 (e.g., frequencies, percentages). 99
Level 4: The literature contains case reports. 100
Insufficient Literature: The lack of sufficient scientific evidence in the literature may occur 101 when the evidence is either unavailable (i.e., no pertinent studies found) or inadequate. Inadequate 102 literature cannot be used to assess relationships among clinical interventions and outcomes because 103 a clear interpretation of findings is not obtained due to methodological concerns (e.g., confounding 104 of study design or implementation), or the study does not meet the criteria for content as defined in 105 the "Focus" of the Guidelines. 106
Opinion-Based Evidence: 107
All opinion-based evidence (e.g., survey data, open-forum testimony, internet-based comments, 108 letters, and editorials) relevant to each topic was considered in the development of these updated 109
Guidelines. However, only the findings obtained from formal surveys are reported in the current 110 update. 111 Identification of patients with risk factors for respiratory depression includes conducting a 136 focused history (e.g., reviewing medical records) and physical examination. 137
Literature findings: Although it is well accepted clinical practice to review medical records and 138 conduct a physical examination, comparative studies are insufficient to directly evaluate the impact 139 of these practices. Studies with observational findings and case reports suggest that certain patient 140 or clinical characteristics (e.g., obesity, obstructive sleep apnea, coexisting disease) may be 141 associated with respiratory depression when neuraxial opioids are used (Category B1/B4-H 142 evidence).
1-5 143
Survey findings: Both the consultants and ASA members strongly agree that (1) a focused 144 history and physical examination should be conducted before administering neuraxial opioids, (2) 145 particular attention should be directed toward signs, symptoms, or a history of sleep apnea, co-146 existing diseases or conditions, current medications, and adverse effects following opioid 147 administration, and (3) a physical examination should include, but is not limited to, baseline vital 148 signs, airway, heart, lung, and cognitive function. 149
Recommendations for identification of patients at increased risk of respiratory depression. 150
• Conduct a focused history and physical examination before administering neuraxial 151
opioids. 152
o Direct particular attention toward signs, symptoms, or a history of sleep apnea, 153 co-existing diseases or conditions (e.g., diabetes, obesity), current medications 154 (including preoperative opioids), and adverse effects following opioid 155
administration. 156
o A physical examination should include, but is not limited to, baseline vital signs, 157 airway, heart, lung, and cognitive function. 158
Prevention of Respiratory Depression after Neuraxial Opioid Administration 159
Prevention of respiratory depression includes consideration of noninvasive positive pressure 160 ventilation and drug selection. Drug selection includes (1) route of administration, (2) type of drug, 161 (i.e., hydrophilic or lipophilic opioids), (3) dose selection, and (4) Survey findings for detection of respiratory depression: Both the consultants and ASA 296 members strongly agree that (1) all patients receiving neuraxial opioids should be monitored for 297 adequacy of ventilation, oxygenation, and level of consciousness and (2) 
Monitoring after administration of single-injection neuraxial lipophilic opioids: 306
Literature findings: The literature is insufficient to assess whether any time interval is optimal 307 for detecting respiratory depression or reducing risks associated with respiratory depression. 308
Survey findings: Both the consultants and ASA members agree that (1) monitoring should be 309 performed for a minimum of 2 hours after administration, (2) continual (i.e., repeated regularly and 310 frequently in steady rapid succession) monitoring should be performed for the first 20 min after 311 administration, followed by monitoring at least once per hour until 2 hours have passed, and (3) 312 after 2 hours, frequency of monitoring should be dictated by the patient's overall clinical condition 313 and concurrent medications. 314
Monitoring during or after continuous infusion or PCEA with neuraxial lipophilic opioids: 315
Literature findings: The literature is insufficient to assess whether any time interval is optimal 316 for detecting respiratory depression or reducing risks associated with respiratory depression. 317
Survey findings: The consultants and ASA members both strongly agree that monitoring should 318 be performed during the entire time the infusion is in use. The consultants and ASA members both 319 agree that (1) monitoring should be continual for the first 20 minutes after initiation, followed by 320 monitoring at least once per hour until 12 hours have passed, (2) from 12-24 hours, monitor at least 321 once every 2 hours and after 24 hours, monitor at least once every 4 hours, and (3) after 322 discontinuation of (CIE) or PCEA with neuraxial lipophilic opioids, the frequency of monitoring 323 should be dictated by the patient's overall clinical condition and concurrent medications. 324
Monitoring after administration of single-injection neuraxial hydrophilic opioids (not 325 including sustained or extended release epidural morphine): 326
Literature findings: The literature is insufficient to assess whether any time interval is optimal 327 for detecting respiratory depression or reducing risks associated with respiratory depression. 328
Survey findings: Both the consultants and ASA members agree that (1) monitoring should be 329 performed for a minimum of 24 hours after administration and (2) monitoring should be performed 330 at least once per hour for the first 12 hours after administration, followed by monitoring at least 331 once every 2 hours for the next 12 hours (i.e., from 12 to 24 hours). The ASA members agree and 332 the consultants strongly agree that after 24 hours, the frequency of monitoring should be dictated by 333 the patient's overall clinical condition and concurrent medications. 334
Monitoring during or after continuous infusion or PCEA with neuraxial hydrophilic 335

opioids: 336
Literature findings: The literature is insufficient to assess whether any time interval is optimal 337 for detecting respiratory depression or reducing risks associated with respiratory depression. 338
Survey findings: The consultants and ASA members both strongly agree that monitoring should 339 be performed during the entire time the infusion is in use. Further, the consultants and ASA 340 members both agree that (1) monitoring at least once every hour should be performed for the first 341 12 hours after initiation, followed by monitoring at least once every 2 hours for the next 12 hours 342
and (2) after 24 hours, monitoring should be performed at least once every 4 hours. The ASA 343 members agree and the consultants strongly agree that after discontinuation of continuous infusion 344 or PCEA, the frequency of monitoring should be dictated by the patient's overall clinical condition 345 and concurrent medications. 346
Monitoring after administration of sustained or extended-release epidural morphine: 347
Literature findings: The literature is insufficient to assess whether any time interval is optimal 348 for detecting respiratory depression or reducing risks associated with respiratory depression. 349
Survey findings: Both the consultants and ASA members agree that (1) monitoring at least once 350 every hour should be performed during the first 12 hours after administration, and at least once 351 every 2 hours for the next 12 hours (i.e., 12-24 hours) and (2) after 24 hours, monitoring should be 352 performed at least once every 4 hours for a minimum of 48 hours. 353
Recommendations for detection and monitoring for respiratory depression. 354
• Monitor all patients receiving neuraxial opioids for adequacy of ventilation (e.g., 355
respiratory rate, depth of respiration [assessed without disturbing a sleeping patient]), 356 oxygenation (e.g., pulse oximetry when appropriate), and level of consciousness. ‡ ‡
357
• Increased monitoring (e.g., intensity, duration, or additional methods of monitoring) may 358 be warranted for patients at increased risk of respiratory depression (e.g., unstable 359 ‡ ‡ In cases with other concerning signs, it is acceptable to awaken a sleeping patient to assess level of consciousness. medical condition, obesity, obstructive sleep apnea, § § concomitant administration of 360 opioid analgesics or hypnotics by other routes, extremes of age). 361
Single-injection neuraxial lipophilic opioids (e.g., fentanyl): 362
• Monitor for a minimum of 2 hours after administration. 363
• Monitor continually (i.e., repeated regularly and frequently in steady rapid succession *** ) 364
for the first 20 min after administration, followed by monitoring at least once per hour 365 until 2 hours have passed. † † † 366
• After 2 hours, frequency of monitoring should be dictated by the patient's overall 367 clinical condition and concurrent medications. 368
Continuous infusion or PCEA with neuraxial lipophilic opioids: 369
• Monitor during the entire time the infusion is in use. 370
• Monitor continually for the first 20 min after initiation, followed by monitoring at least 371 once per hour until 12 hours have passed. 372
• From 12-24 hours, monitor at least once every 2 hours, and after 24 hours, monitor at 373 least once every 4 hours. 374
• After discontinuation of continuous infusion or PCEA with neuraxial lipophilic opioids, 375 frequency of monitoring should be dictated by the patient's overall clinical condition and 376 concurrent medications. 377 § § "Hospitalized patients who are at increased risk of respiratory compromise from OSA should have continuous pulse oximetry monitoring after discharge from the recovery room. Continuous monitoring may be provided in a critical care or stepdown unit, by telemetry on a hospital ward, or by a dedicated, appropriately trained professional observer in the patient's room. Continuous monitoring should be maintained as long as patients remain at increased risk. 
Single-injection neuraxial hydrophilic opioids (e.g., morphine, not including sustained or 378 extended release epidural morphine): 379
• Monitor for a minimum of 24 hours after administration. 380
• Monitor at least once per hour for the first 12 hours after administration, followed by 381 monitoring at least once every 2 hours for the next 12 hours (i.e., from 12 to 24 hours). 382
• After 24 hours, frequency of monitoring should be dictated by the patient's overall 383 clinical condition and concurrent medications. 384
Continuous infusion or PCEA with neuraxial hydrophilic opioids: 385
• Monitor during the entire time the infusion is in use. 386
• Monitor at least once every hour for the first 12 hours after initiation, followed by 387 monitoring at least once every 2 hours for the next 12 hours. 388
• After 24 hours, monitor at least once every 4 hours. 389
• After discontinuation of continuous infusion or PCEA, frequency of monitoring should 390 be dictated by the patient's overall clinical condition and concurrent medications. 391
Sustained or extended-release epidural morphine: 392
• Monitor at least once every hours during the first 12 hours after administration, and at 393 least once every 2 hours for the next 12 hours (i.e., 12-24 hours). 394
• After 24 hours, monitor at least once every 4 hours for a minimum of 48 hours. 395
Management and Treatment of Respiratory Depression 396
Interventions for management and treatment for respiratory depression considered by these 397
Guidelines include: (1) supplemental oxygen, (2) reversal agents, and (3) • Monitor for a minimum of 24 hours after administration. 516
• Monitor at least once per hour for the first 12 hours after administration, followed by 517 monitoring at least once every 2 hours for the next 12 hours (i.e., from 12 to 24 hours). 518
• After 24 hours, frequency of monitoring should be dictated by the patient's overall 519 clinical condition and concurrent medications. 520
Continuous infusion or PCEA with neuraxial hydrophilic opioids: 521
• Monitor during the entire time the infusion is in use. 522 ‡ ‡ ‡ ‡ In cases with other concerning signs, it is acceptable to awaken a sleeping patient to assess level of consciousness.
§ § § § "Hospitalized patients who are at increased risk of respiratory compromise from OSA should have continuous pulse oximetry monitoring after discharge from the recovery room. Continuous monitoring may be provided in a critical care or stepdown unit, by telemetry on a hospital ward, or by a dedicated, appropriately trained professional observer in the patient's room. Continuous monitoring should be maintained as long as patients remain at increased risk. identified. These articles were reviewed and those meeting the appropriate criteria as outlined in 558 the "Focus" section above were combined with pre-2008 articles used in the previous update, 559 resulting in a total of 167 articles that contained direct linkage-related evidence. A complete 560 bibliography used to develop these Guidelines, organized by section, is available as Supplemental 561 Digital Content 2, http://links.lww.com/ALN/___. 562
Initially, each pertinent study finding was classified and summarized to determine meta-analysis 563 potential. Literature pertaining to 4 evidence linkages contained enough studies with well-defined 564 experimental designs and statistical information sufficient for meta-analyses. These linkages were: 565
(1) single-injection epidural opioids vs intramuscular opioids, (2) continuous infusion epidural 566 opioids vs intravenous opioid infusion, (3) high vs low doses of single-injection epidural opioids, 567 and (4) high vs low doses of single-injection intrathecal opioids. 568
General variance-based effect-size estimates or combined probability tests were obtained for 569 continuous outcome measures, and Mantel-Haenszel odds-ratios were obtained for dichotomous 570 outcome measures. Two combined probability tests were employed as follows: (1) sample. An odds-ratio procedure based on the Mantel-Haenszel method for combining study results 575 using 2 x 2 tables was used with outcome frequency information. An acceptable significance level 576 was set at P < 0.01 (one-tailed). Tests for heterogeneity of the independent studies were conducted 577 to assure consistency among the study results. DerSimonian-Laird random-effects odds ratios were 578 obtained when significant heterogeneity was found (P < 0.01). To control for potential publishing 579 bias, a "fail-safe n" value was calculated. No search for unpublished studies was conducted, and no 580 reliability tests for locating research results were done. To be accepted as significant findings, 581
Mantel-Haenszel odds-ratios must agree with combined test results whenever both types of data are 582 assessed. In the absence of Mantel-Haenszel odds-ratios, findings from both the Fisher and 583 weighted Stouffer combined tests must agree with each other to be acceptable as significant. 584
For the previous update, interobserver agreement among Task Force members and two 585 methodologists was established by interrater reliability testing. Agreement levels using a kappa (κ) 586 statistic for two-rater agreement pairs were as follows: (1) oxygenation, and level of consciousness = 59%, (6) supplemental oxygen administration = 88%, 608 and (7) use of noninvasive positive pressure ventilation = 100%. Fifty-nine percent of the 609 respondents indicated that the Guidelines would have no effect on the amount of time spent on a 610 typical case, and 41% indicated that there would be an increase of the amount of time spent on a 611 typical case with the implementation of these Guidelines. 612 
